<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095988</url>
  </required_header>
  <id_info>
    <org_study_id>AMIRA</org_study_id>
    <secondary_id>2016-002550-20</secondary_id>
    <nct_id>NCT04095988</nct_id>
  </id_info>
  <brief_title>Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)</brief_title>
  <acronym>AMIRA</acronym>
  <official_title>Allogeneic Microbiota-reconstitution (AMR) for the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome - the AMIRA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinikum Ludwigsburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helios Klinikum Krefeld</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assign International, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform a multicenter, 2:1 randomized, double-blinded,
      placebo-controlled trial of AMR in patients with diarrhea predominant-IBS (IBS-D) diagnosed
      according to Rome III criteria and the IBS-QOL questionnaire. Central supply and quality
      control of donor material will be used to control bias.

      Primary endpoint is improvement of IBS-SSS (Severity Score System) compared to baseline.
      Secondary endpoints include changes in IBS-QOL, short term safety and one year follow up to
      control long term effects, safety and changes in and acceptance of donor microbiome after AMR
      using16S rDNA sequencing and quantitative diversity analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study assesses allogeneic microbiota reconstitution (AMR) as novel treatment to improve
      symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome
      (IBS-D).

      The investigators will perform a prospective multicenter, 2:1 randomized, double-blinded,
      placebo-controlled trial of AMR in patients with IBS-D diagnosed according to Rome III
      criteria and the IBS-QOL questionnaire.

      The experimental intervention is an infusion of donor feces via gastroscopy. The placebo
      intervention is an infusion of sterile saline via gastroscopy.

      Planned number of patients included in the study: 42 patients Planned per-protocol group: 33
      patients
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of the IBS-SSS questionnaire &gt; 105 Points compared to baseline</measure>
    <time_frame>90 days after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of IBS-QOL using IBS-QOL-questionnaire compared to baseline</measure>
    <time_frame>90 days and 1 year after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes and acceptance of donor microbiome (16S rDNA-analysis)</measure>
    <time_frame>90 days after intervention</time_frame>
    <description>16S rDNA-analysis for microbiome biodiversity, correlation to IBS-Symptom Severity Score (IBS-SSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events</measure>
    <time_frame>follow-up 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Verum-AMR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving Verum-Allogeneic Microbiota Reconstitution via gastroscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-AMR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving Placebo(Saline)-Infusion via gastroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic microbiota reconstitution</intervention_name>
    <description>gastroscopic microbiota Infusion (Verum)</description>
    <arm_group_label>Verum-AMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo-Allogeneic microbiota reconstitution</intervention_name>
    <description>gastroscopic saline Infusion (placebo)</description>
    <arm_group_label>Placebo-AMR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  irritable bowel syndrome of diarrhea-predominant type according to ROME III criteria

          -  Symptoms for &gt; 1 year before study inclusion

          -  persisting symptoms &gt; 1 year before study inclusion

          -  relevant symptoms with reduced Quality of Life (IBS-QOL &lt; 60 Points)

          -  no specific findings in gastroscopy and colonoscopy with biopsies in the last 2 years

        Exclusion Criteria:

          -  chronic inflammatory diseases

          -  gastrointestinal infectious diseases

          -  microscopic colitis

          -  celiac disease

          -  diarrhea caused by fructose- or lactose intolerance

          -  gastrointestinal malignancies or intestinal polyps

          -  irritable bowel syndrome of other type than IBS-D

          -  bile acid diarrhea

          -  constipation

          -  symptoms caused by other diseases than IBS-D

          -  dementia

          -  abdominal surgery in the last months

          -  antibiotic therapy in the last 3 months

          -  pregnancy

          -  linguistic barrier for informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas TW Seufferlein, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Wagner, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Frieling, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Klinikum Krefeld</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helios Klinikum Krefeld</name>
      <address>
        <city>Krefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm University Hospital</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, Hyland L, Morgan A, Maysey J, Moore-Jones D. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust. 1989 May 15;150(10):604.</citation>
    <PMID>2783214</PMID>
  </reference>
  <reference>
    <citation>Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012 Jun;24(6):521-30, e248. doi: 10.1111/j.1365-2982.2012.01891.x. Epub 2012 Feb 20.</citation>
    <PMID>22339879</PMID>
  </reference>
  <reference>
    <citation>Crouzet L, Gaultier E, Del'Homme C, Cartier C, Delmas E, Dapoigny M, Fioramonti J, Bernalier-Donadille A. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil. 2013 Apr;25(4):e272-82. doi: 10.1111/nmo.12103. Epub 2013 Feb 25.</citation>
    <PMID>23433203</PMID>
  </reference>
  <reference>
    <citation>El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002 Jun;16(6):1171-85.</citation>
    <PMID>12030961</PMID>
  </reference>
  <reference>
    <citation>Frieling T, Meis K, Kolck UW, Homann J, Hülsdonk A, Haars U, Hertfelder HJ, Oldenburg J, Seidel H, Molderings GJ. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol. 2011 Feb;49(2):191-4. doi: 10.1055/s-0029-1245707. Epub 2011 Feb 4.</citation>
    <PMID>21298604</PMID>
  </reference>
  <reference>
    <citation>Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010 Sep;44(8):551-61. doi: 10.1097/MCG.0b013e3181e5d06b.</citation>
    <PMID>20716985</PMID>
  </reference>
  <reference>
    <citation>Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013 Mar-Apr;4(2):125-35. doi: 10.4161/gmic.23571. Epub 2013 Jan 18.</citation>
    <PMID>23333862</PMID>
  </reference>
  <reference>
    <citation>Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008 Jan 1;27(1):48-57. Epub 2007 Oct 5.</citation>
    <PMID>17919270</PMID>
  </reference>
  <reference>
    <citation>Kashyap PC, Marcobal A, Ursell LK, Larauche M, Duboc H, Earle KA, Sonnenburg ED, Ferreyra JA, Higginbottom SK, Million M, Tache Y, Pasricha PJ, Knight R, Farrugia G, Sonnenburg JL. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology. 2013 May;144(5):967-77. doi: 10.1053/j.gastro.2013.01.047. Epub 2013 Feb 1.</citation>
    <PMID>23380084</PMID>
  </reference>
  <reference>
    <citation>Keller J, Wedel T, Seidl H, Kreis ME, Andresen V, Preiss JC, Layer P, van der Voort I. [S3 guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM) to the definition, pathophysiology, diagnosis and treatment of intestinal motility]. Z Gastroenterol. 2011 Mar;49(3):374-90. doi: 10.1055/s-0029-1245993. Epub 2011 Mar 9. German.</citation>
    <PMID>21391171</PMID>
  </reference>
  <reference>
    <citation>Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91. Review. Erratum in: Gastroenterology. 2006 Aug;131(2):688.</citation>
    <PMID>16678561</PMID>
  </reference>
  <reference>
    <citation>Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi: 10.1016/j.cgh.2012.02.029. Epub 2012 Mar 15.</citation>
    <PMID>22426087</PMID>
  </reference>
  <reference>
    <citation>Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163-73. doi: 10.1038/nrgastro.2010.4. Epub 2010 Jan 26. Review.</citation>
    <PMID>20101257</PMID>
  </reference>
  <reference>
    <citation>Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil. 2012 Jan;24(1):31-9. doi: 10.1111/j.1365-2982.2011.01803.x. Epub 2011 Nov 9.</citation>
    <PMID>22070725</PMID>
  </reference>
  <reference>
    <citation>Rajilić-Stojanović M, Heilig HG, Tims S, Zoetendal EG, de Vos WM. Long-term monitoring of the human intestinal microbiota composition. Environ Microbiol. 2012 Oct 15. doi: 10.1111/1462-2920.12023. [Epub ahead of print]</citation>
    <PMID>23286720</PMID>
  </reference>
  <reference>
    <citation>Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. Epub 2012 Jun 22.</citation>
    <PMID>22730468</PMID>
  </reference>
  <reference>
    <citation>Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May;136(6):1979-88. doi: 10.1053/j.gastro.2009.02.074. Epub 2009 May 7. Review.</citation>
    <PMID>19457422</PMID>
  </reference>
  <reference>
    <citation>van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.</citation>
    <PMID>23323867</PMID>
  </reference>
  <reference>
    <citation>Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014 Jan;29(1):52-9. doi: 10.1111/jgh.12322.</citation>
    <PMID>23829297</PMID>
  </reference>
  <reference>
    <citation>Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014 Nov 5;312(17):1772-8. doi: 10.1001/jama.2014.13875. Erratum in: JAMA. 2015 Feb 17;313(7):729.</citation>
    <PMID>25322359</PMID>
  </reference>
  <reference>
    <citation>Frieling T. [Functional and inflammatory bowel disorders]. Med Klin (Munich). 2006 Mar 22;101 Suppl 1:139-42. German.</citation>
    <PMID>16802539</PMID>
  </reference>
  <reference>
    <citation>Kleger A, Schnell J, Essig A, Wagner M, Bommer M, Seufferlein T, Härter G. Fecal transplant in refractory Clostridium difficile colitis. Dtsch Arztebl Int. 2013 Feb;110(7):108-15. doi: 10.3238/arztebl.2013.0108. Epub 2013 Feb 15.</citation>
    <PMID>23468820</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Thomas Seufferlein</investigator_full_name>
    <investigator_title>Director Department of Internal Medicine I</investigator_title>
  </responsible_party>
  <keyword>Allogeneic microbiota reconstitution</keyword>
  <keyword>diarrhea-predominant irritable bowel syndrome</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

